Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: Implication of Parkinson disease

NeuroSignals

Volumn 19, Issue 2, 2011, Pages 86-96

  Chung, Ji Yun ^a   Lee, Su Jin ^a   Lee, Sun Hye ^a   Jung, Youn Sang ^a   Ha, Nam Chul ^a   Seol, Wongi ^b   Park, Bum Joon ^a  

^a Pusan National University   (South Korea)

^b Inje University   (South Korea)

Author keywords

Synuclein; AKT; IGF 1 signaling; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DOXORUBICIN; NERVE GROWTH FACTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PARKINSON DISEASE; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SOLUBILITY; WILD TYPE;

ALPHA-SYNUCLEIN; CELL LINE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 79958115666     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000325028     Document Type: Article

References (28)

1. Thomas B, Beal MF: Parkinson's disease. Hum Mol Genet 2007;16:183-194.
2. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A: Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-252. (Pubitemid 30316525)
3. Licker V, Kövari E, Hochstrasser DF, Burkhard PR: Proteomics in human Parkinson's disease research. J Proteomics 2009;73:10-29.
4. Kumari U, Tan EK: LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 2009;276:6455-6463.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alphasynuclein in Lewy bodies. Nature 1997;388:39-40.
6. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoin S, Crawley A, Hanson M, Maraganore E, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K: Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841. (Pubitemid 37339619)
7. Yavich L, Jakala P, Tanila H: Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in α-synuclein knockout and A30P transgenic mice. J Neurochem 2006;99:724-732. (Pubitemid 44583432)
8. Goedert M: Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
9. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA: Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110-114. (Pubitemid 29214817)
10. Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H: Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000;47:521-523. (Pubitemid 30194611)
11. Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I: Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett 2001;316:129-132. (Pubitemid 34020746)
12. Kao SY: Rescue of α-synuclein cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun 2009;385:434-438.
13. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del-Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW: Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158-1160. (Pubitemid 38661852)
14. Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA: The Parkinson's disease-associated DJ-1 protein is a transcriptional coactivator that protects against neuronal apoptosis. Hum Mol Genet 2005;14:1231-1241. (Pubitemid 40613911)
15. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijin CM, Oostra BA, Heutink P: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
16. Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, Abuin A, Grau E, Geppert M, Livi GP, Creasy CL, Martin A, Hargreaves I, Heales SJ, Okada H, Brandner S, Schulz JB, Mak T, Downward J: Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004;24:9848-9862. (Pubitemid 39458812)
17. Fountaine TM, Wade-Martins R: RNA interference-mediated knockdown of α-synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport. J Neurosci Res 2007;85:351-363. (Pubitemid 46219303)
18. Lee SH, Lee SJ, Jung YS, Xu Y, Kang HS, Ha NC, Park BJ: Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 2009;11:22-31.
19. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-267.
20. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R: Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998;58:2331-2334. (Pubitemid 28252688)
21. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009;325:1134-1138.
22. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB: Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004;62:1835-1838. (Pubitemid 38661745)
23. Kumar CC, Madison V: AKT crystal structure and AKT-specific inhibitors. Oncogene 2005;24:7493-7501. (Pubitemid 41637989)
24. Brugge J, Hung MC, Mills GB: A new mutational AKT activation in the PI3K pathway. Cancer Cell 2007;12:104-107. (Pubitemid 47199129)
25. Zaka M, Rafi MA, Rao HZ, Luzi P, Wenger DA: Insulin-like growth factor-1 provides protection against psychosine-induced apoptosis in cultured mouse oligodendrocyte progenitor cells using primarily the PI3K/Akt pathway. Mol Cell Neurosci 2005;30:398-407. (Pubitemid 41416557)
26. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM: Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-386. (Pubitemid 46184217)
27. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047. (Pubitemid 27443610)
28. Hardy J, Cookson MR, Singleton A: Genes and parkinsonism. Lancet Neurol 2003;2:221-228. (Pubitemid 37443309)